UBS analyst Jay Sole raised the firm’s price target on Bath & Body Works to $44 from $34 and keeps a Neutral rating on the shares. Softlines growth stocks have historically been the best performers over 12-month time horizons, and UBS expects the trend to continue and for growth stocks to outperform through what is likely another year of high volatility, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BBWI:
- Bath & Body Works downgraded to Equal Weight from Overweight at Barclays
- The beauty and wellness stocks to own in 2024, according to Piper Sandler
- Bath & Body Works price target raised to $40 from $34 at Piper Sandler
- Bath & Body Works downgraded to Buy from Conviction Buy at Goldman Sachs
- Bath & Body Works price target raised to $40 from $35 at Wells Fargo
